Pain in Inflammatory Joint Diseases

NCT ID: NCT06718569

Last Updated: 2025-05-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-31

Study Completion Date

2027-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory arthritis, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthritis Arthritis, Juvenile Idiopathic Arthritis,Rheumatoid Arthritis, Reactive Arthritis, Psoriatic Spondyloarthritis (SpA)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients who initiate or switch biological or targeted synthetic DMARD

All patients initiate or switch biological or targeted synthetic DMARD

Biological or targeted synthetic DMARD

Intervention Type DRUG

All biological or targeted synthetic DMARDs that are available for treatment of patients with inflammatory joint diseases

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological or targeted synthetic DMARD

All biological or targeted synthetic DMARDs that are available for treatment of patients with inflammatory joint diseases

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients who initiate or switch biological or targeted synthetic DMARDs

Exclusion Criteria

* None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Oslo

OTHER

Sponsor Role collaborator

Diakonhjemmet Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ida Kristin Haugen

MD PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ida K Haugen, MD PhD

Role: CONTACT

+47 95859884

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

708967

Identifier Type: OTHER

Identifier Source: secondary_id

DS-00850

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

EMDR for Persistent Pain in RA
NCT05941559 ENROLLING_BY_INVITATION NA
Remote Care in People With Rheumatoid Arthritis
NCT05496855 ACTIVE_NOT_RECRUITING NA